Gyre Therapeutics Q2 EPS $(0.12) Misses $(0.04) Estimate, Sales $29.105M Beat $26.490M Estimate
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.04) by 200 percent. The company reported quarterly sales of $29.105 million which beat
Gyre Therapeutics made more money than expected from selling products, which is good. But they lost more money than expected overall, which means their costs were higher than people thought.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.